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Background
•

In 2016 ACOG recommended use of daily aspirin to prevent
preeclampsia in selected high risk pregnancies

•

There has been limited study on the implementation of this
recommendation

•

OBJECTIVE: To evaluate the utilization of aspirin for
preeclampsia prevention before and after implementation of a
screening tool at 11-13 week ultrasound

Materials and Methods
•

•

One year prospective cohort study (2018) of patients at high risk
for preeclampsia after the implementation of a screening tool
(post-screen) administered to all patients at check in for an 11-13
week ultrasound.
Screening tool completed by patient at check in, surveyed presence
of high risk factors for preeclampsia. Patients also surveyed for
adherence through pregnancy

•

Prospective cohort compared to a retrospective cohort (2017)

•

Obstetric history, antenatal complications, and aspirin
recommendation determined by chart review in both cohorts

•

Primary outcome: provider recommendation for aspirin therapy

Results
•

Pre-screen (N=156) and post-screen (N=136) cohorts similar
except for race and multifetal gestation

•

Overall, recommendation for aspirin therapy improved
post-screen vs pre-screen (95% vs 74%, p<0.001)

•

High risk women without prior preeclampsia were less
likely to be prescribed aspirin pre vs post-screen (64% vs
95%, p<0.001)

•

Adjusting for baseline differences, post-screen was associated with
an increased odds of high risk women receiving aspirin (OR 10.0
(3.7-26.8), p<.001)

•

109 women completed initial survey, 88% initiated aspirin by 20
weeks’. The most common reason for not was that patient “forgot
but planned to” (31%) or “did not think it would help” (31%)

•

104 women completed third trimester survey, 91% reported still
taking aspirin, and 75% reported rarely or never missing a dose

Figure 1: Provider Recommendation for Aspirin by
Risk Factor Pre- and Post- Screening Tool
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Figure 2: Aspirin Adherence in High Risk Pregnant Women

